CALCA and medullary thyroid gland carcinoma: Standardization of methods should be further ameliorated and large prospective multicentric validation is desirable to refine clinical thresholds of different markers, evaluate candidate biomarkers, and address rare clinical scenarios, such as calcitonin-negative MTC.